Researchers then explored the relationship between HIGD1B and clinicopathological elements, TME, and immune cell infiltration of GC, thoroughly and systematically evaluated the diagnostic and prognostic value of HIGD1B in GC, predicted the effectiveness of chemotherapy and immunotherapy, and ultimately identified HIGD1B as a novel prognostic biomarker for GC. Here, HIGD1B is linked to gastric cancer.